Anna Kaltenboeck
@annakal.bsky.social
Health econ & Rx drug pricing. 💵💲💉💊Opinions my own.
Reposted by Anna Kaltenboeck
Scoop: Vinay Prasad is out at FDA. HHS spokesperson said "he did not want to be a distraction to the great work of the FDA in the Trump administration."
Story TK in Pink Sheet.
Story TK in Pink Sheet.
July 30, 2025 at 12:57 AM
Scoop: Vinay Prasad is out at FDA. HHS spokesperson said "he did not want to be a distraction to the great work of the FDA in the Trump administration."
Story TK in Pink Sheet.
Story TK in Pink Sheet.
🚨 Top 5 Takeaways from our 2024 Biopharma Wrap-Up 🚨
Every 6 months, my team and I review biopharma R&D and investment decisions. Our latest report examines 2024. Much of the last year was shaped by the ongoing race to fill impending revenue gaps as older drugs face LOE. More below 👇
Every 6 months, my team and I review biopharma R&D and investment decisions. Our latest report examines 2024. Much of the last year was shaped by the ongoing race to fill impending revenue gaps as older drugs face LOE. More below 👇
April 19, 2025 at 1:22 PM
🚨 Top 5 Takeaways from our 2024 Biopharma Wrap-Up 🚨
Every 6 months, my team and I review biopharma R&D and investment decisions. Our latest report examines 2024. Much of the last year was shaped by the ongoing race to fill impending revenue gaps as older drugs face LOE. More below 👇
Every 6 months, my team and I review biopharma R&D and investment decisions. Our latest report examines 2024. Much of the last year was shaped by the ongoing race to fill impending revenue gaps as older drugs face LOE. More below 👇
Reposted by Anna Kaltenboeck
🩺📊 #medsky
New piece led by Anushka Bhaskar @portalresearch.org in STAT First Opinion on protecting public health agencies from damaging political interference -- even the threat of which can greatly affect people's behavior: www.statnews.com/2025/01/31/p...
How to protect HHS, FDA, NIH, and other health agencies from political interference
When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts and inflict lasting damage on institutional credibility.
www.statnews.com
January 31, 2025 at 4:11 PM
🩺📊 #medsky
Reposted by Anna Kaltenboeck
I had a chance to join CBS News and Major Garrett to discuss my recent @newyorker.com piece on the consequences of money in medicine. Is U.S. health care entering a "gilded age"?
Is U.S. health care in a "gilded age"?
A New Yorker article argues that we are in "the gilded age of medicine." So what does that mean for U.S. health care? Dr. Dhruv Khullar, associate professor of health and economics at Weill Cornell Me...
www.cbsnews.com
December 19, 2024 at 7:45 PM
I had a chance to join CBS News and Major Garrett to discuss my recent @newyorker.com piece on the consequences of money in medicine. Is U.S. health care entering a "gilded age"?
Reposted by Anna Kaltenboeck
Vertex $VRTX touts pain drug results, but medicine does not outperform placebo in sciatica study www.statnews.com/2024/12/19/v... via @matthewherper.bsky.social
Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study
A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.
www.statnews.com
December 19, 2024 at 12:09 PM
Vertex $VRTX touts pain drug results, but medicine does not outperform placebo in sciatica study www.statnews.com/2024/12/19/v... via @matthewherper.bsky.social
Reposted by Anna Kaltenboeck
At @kff.org, we’ve been busy updating our interactive with national health spending data released yesterday.
Explore trends in US health care costs from 1960-2023 and make your own charts using this tool:
www.healthsystemtracker.org/health-spend...
Explore trends in US health care costs from 1960-2023 and make your own charts using this tool:
www.healthsystemtracker.org/health-spend...
National Health Spending Explorer - Peterson-KFF Health System Tracker
This interactive tool provides up-to-date information on U.S. health spending by federal and local governments, private companies, and individuals. It was developed by KFF using data from the National...
www.healthsystemtracker.org
December 19, 2024 at 8:41 PM
At @kff.org, we’ve been busy updating our interactive with national health spending data released yesterday.
Explore trends in US health care costs from 1960-2023 and make your own charts using this tool:
www.healthsystemtracker.org/health-spend...
Explore trends in US health care costs from 1960-2023 and make your own charts using this tool:
www.healthsystemtracker.org/health-spend...
Reposted by Anna Kaltenboeck
Every drug I used when I took care of kids with cancer had serious risks.
The only thing that could justify my using them was that their benefits outweighed their risks.
But without proof of efficacy, there’s no way to make that calculation.
Safety & efficacy are 2 sides of the same coin.
The only thing that could justify my using them was that their benefits outweighed their risks.
But without proof of efficacy, there’s no way to make that calculation.
Safety & efficacy are 2 sides of the same coin.
HHS Deputy Secretary pick Jim O’Neill, believes the FDA should only consider safety and not efficacy when making approval decisions.
Someone should let him know that taking ineffective medical products DOES affect patient safety.
thehill.com/homenews/adm...
Someone should let him know that taking ineffective medical products DOES affect patient safety.
thehill.com/homenews/adm...
Jim O’Neill selected to lead HHS alongside RFK Jr. as deputy
President-elect Trump’s choice for deputy secretary of Health and Human Services is Jim O’Neill, an investor and historically close associate of billionaire Peter Thiel, the president-e…
thehill.com
November 27, 2024 at 8:39 PM
Every drug I used when I took care of kids with cancer had serious risks.
The only thing that could justify my using them was that their benefits outweighed their risks.
But without proof of efficacy, there’s no way to make that calculation.
Safety & efficacy are 2 sides of the same coin.
The only thing that could justify my using them was that their benefits outweighed their risks.
But without proof of efficacy, there’s no way to make that calculation.
Safety & efficacy are 2 sides of the same coin.
Reposted by Anna Kaltenboeck
A costly symptom of our complicated drug reimbursement system: People in the same Medicare drug plan face wildly different prices for the same drug
Medicare Pays Wildly Different Prices for the Same Drug
Middlemen negotiate prescription costs at thousands of different price points, depending on your insurance plan.
www.wsj.com
November 26, 2024 at 1:33 PM
A costly symptom of our complicated drug reimbursement system: People in the same Medicare drug plan face wildly different prices for the same drug
Reposted by Anna Kaltenboeck
We are hiring new fellows and faculty in PORTAL. Please reach out if interested! And spread the word.
📣PORTAL is hiring! 📣
There are less than 2 weeks left to apply for our Postdoctoral and General Medicine Fellowships, both with a focus on pharmaceutical law, health policy, and health services research. Apply by December 1, 2024.
Learn more: mailchi.mp/3e02f38a708b/portal-hiring-2025
There are less than 2 weeks left to apply for our Postdoctoral and General Medicine Fellowships, both with a focus on pharmaceutical law, health policy, and health services research. Apply by December 1, 2024.
Learn more: mailchi.mp/3e02f38a708b/portal-hiring-2025
Deadline Approaching - Join the PORTAL Team!
Apply by December 1, 2024 to be a PORTAL Postdoctoral or General Medicine Fellow. We are also accepting applications for a Faculty Member in Health Policy or Health Services Research.
mailchi.mp
November 21, 2024 at 5:36 PM
We are hiring new fellows and faculty in PORTAL. Please reach out if interested! And spread the word.
Reposted by Anna Kaltenboeck
How to write a scientific paper in four slides.
Full guide here: www.surgeryredesign.com/s/WritingFor...
YouTube format here: youtu.be/fgeahUrXVaY?...
#meded #medsky #research
Full guide here: www.surgeryredesign.com/s/WritingFor...
YouTube format here: youtu.be/fgeahUrXVaY?...
#meded #medsky #research
November 17, 2024 at 10:35 PM
How to write a scientific paper in four slides.
Full guide here: www.surgeryredesign.com/s/WritingFor...
YouTube format here: youtu.be/fgeahUrXVaY?...
#meded #medsky #research
Full guide here: www.surgeryredesign.com/s/WritingFor...
YouTube format here: youtu.be/fgeahUrXVaY?...
#meded #medsky #research
Reposted by Anna Kaltenboeck
On the DHHS and CMS news, I will not allow MAHA. I may allow for MWAHA because, sarcasm.
Health journalists and academics, say no to the acronym. First act of resistance. ##healthpolicy #youmustbejoking
Health journalists and academics, say no to the acronym. First act of resistance. ##healthpolicy #youmustbejoking
a cartoon character wearing a hoodie is laughing in front of a fire background .
ALT: a cartoon character wearing a hoodie is laughing in front of a fire background .
media.tenor.com
November 20, 2024 at 2:10 AM
On the DHHS and CMS news, I will not allow MAHA. I may allow for MWAHA because, sarcasm.
Health journalists and academics, say no to the acronym. First act of resistance. ##healthpolicy #youmustbejoking
Health journalists and academics, say no to the acronym. First act of resistance. ##healthpolicy #youmustbejoking
I already have a headache sorting signal from noise and it‘s not even 2025 yet. Gonna be a while before we have a clear picture of what this means for Rx.
www.axios.com/2024/11/19/r...
www.axios.com/2024/11/19/r...
RFK Jr. vs. Vivek: Trump world's two paths for pharma regulation
Between RFK Jr. and Vivek Ramaswamy, the incoming Trump administration has widely divergent views on regulating the drug industry.
www.axios.com
November 20, 2024 at 2:16 PM
I already have a headache sorting signal from noise and it‘s not even 2025 yet. Gonna be a while before we have a clear picture of what this means for Rx.
www.axios.com/2024/11/19/r...
www.axios.com/2024/11/19/r...
Reposted by Anna Kaltenboeck
"We’ve had members and manufacturers say, OK we will not invest in developing a biosimilar in Medicare Part D or in the PBM space, if the PBM system does not change.” - Juliana Reed of the Biosimilars Forum #healthpolicy
Time To Tip the Scales? Humira Biosimilars And The Limitations Of Competition In US Health Care
<p>In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting. </p>
pink.citeline.com
February 1, 2024 at 4:11 PM
"We’ve had members and manufacturers say, OK we will not invest in developing a biosimilar in Medicare Part D or in the PBM space, if the PBM system does not change.” - Juliana Reed of the Biosimilars Forum #healthpolicy
A big congrats to Biden administration and CMMI on moving forward with a novel payment approach for cell and gene therapies! www.cms.gov/newsroom/pre...
November 19, 2024 at 7:27 PM
A big congrats to Biden administration and CMMI on moving forward with a novel payment approach for cell and gene therapies! www.cms.gov/newsroom/pre...
Incentive for R&D is always a topic in Pharma policy, but debate usually focuses on investment and development. I fear the pressure to show novelty at the bench is being overlooked. How much money and effort is going into chasing scientific dead ends? www.statnews.com/2024/01/19/d...
November 19, 2024 at 7:27 PM
Incentive for R&D is always a topic in Pharma policy, but debate usually focuses on investment and development. I fear the pressure to show novelty at the bench is being overlooked. How much money and effort is going into chasing scientific dead ends? www.statnews.com/2024/01/19/d...
Reposted by Anna Kaltenboeck
For any docs out there who struggle with prior auth and would love to have your biases confirmed, I highly recommend this new study by @michaelannica.bsky.social and Nancy Keating, out yesterday in JCO:
pubmed.ncbi.nlm.nih.gov/38086013/
1/
pubmed.ncbi.nlm.nih.gov/38086013/
1/
December 13, 2023 at 4:00 PM
For any docs out there who struggle with prior auth and would love to have your biases confirmed, I highly recommend this new study by @michaelannica.bsky.social and Nancy Keating, out yesterday in JCO:
pubmed.ncbi.nlm.nih.gov/38086013/
1/
pubmed.ncbi.nlm.nih.gov/38086013/
1/
Reposted by Anna Kaltenboeck
NON-profit hospitals — what’s in a name?
Check out my @nytimes.com oped asking nonprofit boards to come back to their mission
www.nytimes.com/2023/11/30/o...
@sangerkatz.bsky.social @dusetzinas.bsky.social @stevejoffe.bsky.social
Check out my @nytimes.com oped asking nonprofit boards to come back to their mission
www.nytimes.com/2023/11/30/o...
@sangerkatz.bsky.social @dusetzinas.bsky.social @stevejoffe.bsky.social
Opinion | How to Put ‘Community’ Back in the Mission of Community Hospitals
Nonprofit hospitals are behaving in ways that seem to focus more on dollars than patients.
www.nytimes.com
November 30, 2023 at 1:09 PM
NON-profit hospitals — what’s in a name?
Check out my @nytimes.com oped asking nonprofit boards to come back to their mission
www.nytimes.com/2023/11/30/o...
@sangerkatz.bsky.social @dusetzinas.bsky.social @stevejoffe.bsky.social
Check out my @nytimes.com oped asking nonprofit boards to come back to their mission
www.nytimes.com/2023/11/30/o...
@sangerkatz.bsky.social @dusetzinas.bsky.social @stevejoffe.bsky.social
In a recent Health Affairs Forefront post, National Pharmaceutical Council put forward cherry-picked examples to argue that Medicare negotiation will harm incentives to innovate. The problem: their own examples show the opposite. Here’s our response. @dusetzinas.bsky.social @bnrome.bsky.social
www.healthaffairs.org
November 19, 2024 at 7:27 PM
In a recent Health Affairs Forefront post, National Pharmaceutical Council put forward cherry-picked examples to argue that Medicare negotiation will harm incentives to innovate. The problem: their own examples show the opposite. Here’s our response. @dusetzinas.bsky.social @bnrome.bsky.social
Reposted by Anna Kaltenboeck
What professional development topics do you wish you learned about in grad school (in a PhD program, in particular)? #healthpolicy
November 28, 2023 at 5:56 PM
What professional development topics do you wish you learned about in grad school (in a PhD program, in particular)? #healthpolicy
This would be such an long-overdue win for those living with Hepatitis C. www.nytimes.com/2023/11/28/o...
November 19, 2024 at 7:27 PM
This would be such an long-overdue win for those living with Hepatitis C. www.nytimes.com/2023/11/28/o...
Reposted by Anna Kaltenboeck
Will be key to keep track of FDA's success in this effort to get needed long-term data on gene therapies. #healthpolicy
pink.citeline.com/PS149041/US-...
pink.citeline.com/PS149041/US-...
US FDA Struggling With Long-Term Follow-Up Requirements For Gene Therapies
<p>OTP Director Nicole Verdun acknowledged the agency may need help to determine how to ensure 15 years of patient follow-up is completed despite physician retirements, company closures and other issu...
pink.citeline.com
October 19, 2023 at 2:15 PM
Will be key to keep track of FDA's success in this effort to get needed long-term data on gene therapies. #healthpolicy
pink.citeline.com/PS149041/US-...
pink.citeline.com/PS149041/US-...
Reposted by Anna Kaltenboeck
I think this $NOVO suit may be one of the most interesting to watch in terms of the Medicare negotiation challenges. #healthpolicy
Novo Files Suit Over IRA As It Joins Others In Signing On To Price Negotiations
<p>The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Red...
pink.citeline.com
October 3, 2023 at 4:38 PM
I think this $NOVO suit may be one of the most interesting to watch in terms of the Medicare negotiation challenges. #healthpolicy